Precautions when using 0.01% atropine sulfate eye drops

0.01% Atropine Sulfate Eye Drops (EIKANCE), as a low-concentration atropine preparation, has received widespread attention in the field of myopia control in recent years. Although its safety and effectiveness are significantly improved compared to high-concentration atropine, several key matters still need to be paid attention to during clinical use to ensure maximum therapeutic effect and patient safety. First of all, patients should undergo detailed examination and evaluation by a professional ophthalmologist before using EIKANCE. This drug is mainly used to control myopia in children and adolescents, and it is usually recommended to start treatment in the early stages of myopia or the stage of active visual axis growth. Therefore, accurate refractive status assessment and axial measurement are the basis for formulating a reasonable treatment plan to avoid ineffective or over-treatment.

During use, patients and parents must strictly follow the doctor's instructions for taking the medication, usually one drop before going to bed every day. Since the mechanism of action of the drug is to slow down the spasm and axial growth of the eye by blocking choline receptors in the eye, regular medication is very important, and any missed use or arbitrary discontinuation may affect the efficacy. On the other hand, although EIKANCE's low-concentration design effectively reduces side effects such as mydriasis and weakened accommodation caused by traditional atropine, some patients may still experience discomfort reactions such as mild eye irritation, dryness, or temporary vision fluctuations. These symptoms are usually more common in the early stages of use, and most of them will gradually alleviate as the medication time is extended. Therefore, patients should inform their doctors of any abnormal feelings, and doctors will need to adjust treatment plans or provide corresponding support based on symptoms.

In addition, regular follow-up is a key link to ensure the safety and efficacy of treatment. Ophthalmologists recommend that patients undergo a vision and axial examination at least every 3 to 6 months to assess the progression of myopia and detect potential side effects early. Especially for pediatric patients, the axial length of the eye may change rapidly during the rapid growth stage, so it is particularly important to adjust treatment strategies in a timely manner. In addition, parents need to pay attention to children's medication compliance, ensure correct use and storage of eye drops, and avoid weakening of medication efficacy or eye infection due to improper operation.

When using EIKANCE should also be careful not to use it with other eye drugs at the same time, especially eye drops containing preservatives or other active ingredients, which may cause irritation to the cornea or affect drug absorption. For patients with pre-existing eye diseases such as glaucoma, iritis or severe dry eye, the risks need to be carefully assessed before use and treated under the guidance of a professional doctor. In addition, the anticholinergic effect of atropine eye drops may cause mydriasis and sensitivity to light. Patients should avoid strong light stimulation while taking the drug, and it is recommended to wear sunglasses to protect their eyes when going out.

Pregnant and lactating women should use with cautionThere is limited safety data on 0.01% atropine sulfate eye drops, and a doctor must decide whether to use it after fully evaluating the pros and cons. Although there are few studies on the use of EIKANCE for adult myopia patients other than children, they should be used with caution according to medical advice. In addition, the storage conditions of drugs have a significant impact on their stability. It is usually recommended to store them in a cool, dry place away from high temperatures and direct sunlight to prevent the drug from reducing its efficacy or deteriorating. After opening the bottle, the medicine should be used as soon as possible to avoid bacterial contamination caused by long-term storage.

In general,Although 0.01% atropine sulfate eye drops (EIKANCE) is a relatively safe and effective low-concentration myopia control drug, precautions during its use cannot be ignored. Professional ophthalmic diagnosis and follow-up, strict medication compliance, and timely recognition and treatment of possible side effects are all key factors to ensure successful treatment.

Reference materials:https://www.medsafe.govt.nz/profs/datasheet/e/EikanceEyeDrops.pdf